Extending range
without compromise

Discover more

“For many years I have worked on optimising a lens for monovision, given that it accounts for nearly 30% of all surgeries. I collaborated with Rayner on bringing this lens to market as RayOne EMV, an exciting new product for all surgeons looking to treat presbyopia reliably”

Professor Graham Barrett,

President of the Australasian Society of Cataract & Refractive Surgeons

How does RayOne EMV work?

RayOne EMV is a truly non-diffractive IOL which does not use light splitting technology like many IOLs which increase depth of focus1.

RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration to slightly extend the depth of focus.

Compared to a lens with zero spherical aberration, the carefully controlled positive spherical aberration induced by RayOne EMV spreads light along the visual axis.

Centre region

Induced positive spherical aberration

Blended edge region

Reduced longitudinal spherical aberration designed to maintain visual acuity and constrast sensitivity under mesopic conditions.

Clinical results with RayOne EMV

Since the launch of RayOne EMV in 2020, clinical data has demonstrated that RayOne EMV provides high quality vision.1,2,3,6,7

The following clinical results are from patients in the UK, Spain and Portugal during the months leading up to the commercial launch of RayOne EMV.2

RayOne EMV
vs. Zero aberration IOL

1

The patented RayOne EMV optic maintains monofocal-quality distance vision

2

RayOne EMV uniquely redirects light BOTH myopically to extend depth of focus for excellent intermediate vision AND hyperopically for a wider landing zone

3

This unique hyperopic extended depth design also provides enhanced blended binocular vision when used in a monovision configuration

Comparative outcomes with RayOne EMV

At the Hospital da Luz Lisboa in Lisbon, Professor Filomena Ribeiro and Professor Tiago Ferreira led a 150 patient double-arm, non-randomised prospective case series where RayOne EMV demonstrated excellent visual outcomes for distance and intermediate vision, and good visual acuity for near vision.1

RayOne EMV versus TECNIS Eyhance

At the Hospital San Rafael in Madrid, 22 eyes of 11 patients were implanted with RayOne EMV and 70 eyes of 35 patients implanted with TECNIS Eyhance (Johnson & Johnson Vision). Bilateral emmetropia was targeted for all patients. The defocus curve reports the binocular vision obtained using the best distance correction.6

Expand Image

Click to expand

 

  • Single piece IOL created from a homogeneous material free of microvacuoles1
  • Compressible material for delivery through a 2.2 mm micro incision
  • Excellent handling characteristics with controlled unfolding within the capsular bag
  • Low silicone oil adherence2
  • Excellent uveal biocompatibility3
  • Hydrophilic acrylic material with low inflammatory response4
  • 11 million Rayacryl hydrophilic IOL implantations

 

 

  1. Rayner. Data on File (RDTR 1937).
  2. McLoone E, Mahon G, Archer D, Best R. Br J Ophthalmol. 2001; 85:543-545.
  3. Tomlins PJ, Sivaraj RR, Rauz S, Denniston AK, Murray PI. J Cataract Refract Surg. 2014; 40:618-625.
  4. Rayner. Data on File.
  • Proven rotational stability and centration8 with predictable, sustainable and accurate visual results.
  • Average offset of only 0.08 mm 3 to 6 months after surgery8
  • 1.83° mean IOL rotation 3 to 6 months after surgery8

  1. Outer haptics begin to take up the compression forces of post-operative capsule contraction
  2. Outer haptics engage the inner haptics
  3. Haptic tips gently meet the IOL optic and are effectively locked into position
1

Supplied in saline

2

True two-step system

3

Single handed plunger with minimal force required

4

1.65mm nozzle for 2.2mm incision

5

Unique Lock & Roll technology - rolls the lens
inside the injector for a single smooth movement

Videos

Articles & downloads

Learn more about RayOne EMV

This field is for validation purposes and should be left unchanged.
  1. Ferreira TB. Presented at ESCRS 2022.
  2. RayOne EMV: First Clinical Results, Rayner. Oct 2020.
  3. Rayner RayPRO, data on file.
  4. Rayner, data on file.
  5. Rayner Peer2Peer webinar. May 2022.
  6. Royo, M. RayOne EMV and TECNIS Eyhance: A Comparative Clinical Defocus Curve. Data on file. 2021.
  7. How to Choose the Right Solution for Your Patients, CRSTE April 2021.
  8. Bhogal-Bhamra GK, Sheppard AL, Kolli S, Wolffsohn JS. J Refract Surg. 2019;35(1):48-53.

Rayner and RayOne are proprietary marks of Rayner. All other trademarks are property of their respective owners.

PRECAUTION: The safety and effectiveness of the RayOne EMV (RAO200E) has not been substantiated in clinical trials. The effects of the RayOne EMV IOL optical design on quality of vision, contrast sensitivity, and subjective visual disturbances (glare, halo, etc.) have not been evaluated clinically. Certain lab-based testing of the RayOne EMV IOL may aid surgeons in understanding the theoretical image quality expected with the RayOne EMV IOL compared to other Rayner FDA approved lenses, but such testing does not fully assess all aspects of clinical difficulties under all conditions. You must discuss with your surgeon the potential benefits of the modified optical design of the RayOne EMV IOL against the potential for risks associated with a degradation in vision quality and the lack of clinical data to characterize the impact of the RayOne EMV IOL optical design on contrast sensitivity and subjective visual disturbance. These considerations may be especially relevant to patients with certain preexisting ocular conditions (prior eye surgery, irregular corneal astigmatism, severe corneal dystrophy, macular disease, optic nerve atrophy, etc).